Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today will host an Investor Day, which focuses on the global powerhouse's differentiation and durability, including its longtime mission to expand access to medicine, commitment to complex scientific programs and commercial diversification, and significant financial flexibility. Additionally, the presentation highlights recently announced opportunities, including: Mylan's acquisition of the global marketing rights to a once-monthly Glatiramer Acetate product through a partnership with Mapi Pharma; a partnership with Fujifilm Kyowa Kirin Biologics to commercialize a biosimilar to Humira®(adalimumab) in Europe (link to announcement); and Mylan's acquisition of the global development and marketing rights from Prayog Labs for a new, fast-acting formulation of Meloxicam, a non-opioid pain management option. Mylan CEO Heather Bresch commented: "For nearly 60 years, Mylan has remained true to its core purpose of providing access to medicine.